Pacira Pharmaceuticals (NASDAQ:PCRX) has been under a strong bear grip, hence the stock is down -18.74% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 7.32% in the past 1 week. The stock has risen by 8.69% in the past week indicating that the buyers are active at lower levels, but the stock is down -17.43% in the past 4 weeks.
The company shares have dropped -45.78% from its 1 Year high price. On Dec 29, 2015, the shares registered one year high at $80.25 and the one year low was seen on Jun 30, 2016. The 50-Day Moving Average price is $41.43 and the 200 Day Moving Average price is recorded at $54.23.
The stock has recorded a 20-day Moving Average of 5.88% and the 50-Day Moving Average is 17.03%.
Pacira Pharmaceuticals (NASDAQ:PCRX): stock turned positive on Friday. Though the stock opened at $35.94, the bulls momentum made the stock top out at $36.54 level for the day. The stock recorded a low of $35.66 and closed the trading day at $36.39, in the green by 1.48%. The total traded volume for the day was 667,386. The stock had closed at $35.86 in the previous days trading.
In an insider trading activity, The Securities and Exchange Commission has divulged that Brege Laura, director of Pacira Pharmaceuticals, Inc., had unloaded 1,000 shares at an average price of $46.95 in a transaction dated on June 6, 2016. The total value of the transaction was worth $46,950.
Pacira Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is focused on the development, commercialization and manufacture of pharmaceutical products, based on its DepoFoam drug delivery technology, primarily for use in hospitals and ambulatory surgery centers. Its primary focus lies in the development of non-opioid products for postsurgical pain control. DepoFoam is basis for the companys lead product candidate, EXPAREL, a liposome injection of bupivacaine, an amide-type local anesthetic indicated for infiltration into the surgical site to produce postsurgical analgesia. In addition to EXPAREL, DepoFoam is also the basis for its other commercial product, DepoCyt(e), which the Company manufactures for its commercial partners, as well as its other product candidates. The Companys other product candidates include DepoMeloxicam and DepoTranexamic Acid.